2.2. Participants
neurological disease, cardiovascular instability, cognitive impairment, Stroke, ischaemic stroke, epilepsy, dementia, low functional mobility, arteria
NEUROLOGICAL DISEASE, STROKE, EPILEPSY, ISCHAEMIC STROKE, EVENT, SEVERE VISUAL IMPAIRMENT
The study included patients after their first ischaemic stroke in the arteria cerebri media basin (time since the event <6 months) who were referred for rehabilitation for 4 to 5 weeks in a rehabilitation sanatorium in the Czech Republic, between November 2022 and March 2023. Patients were treated according to the European Stroke Organization (ESO) standard operating procedure based on the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) framework. All patients were treated pharmacologically prior to the start of rehabilitation, and during their stay in the rehabilitation facility, they underwent regular medical examinations at least once a week.The inclusion criteria for the study were those aged 40–79 years, in stable condition, with ability to participate, mini-mental state examination score <25 points, intact vision, preserved grip function of the thumb and index finger of the affected limb, and functional mobility according to Functional Ambulatory Category (FAC) 3–5.Study exclusion criteria included: age >40 and <79 years, decompensated state, cardiovascular instability, severe fatal and severe cognitive impairment, low functional mobility according to FAC 0–2, dementia with mini-mental state examination >24 points, severe visual impairment, and personal history of epilepsy. The selected patients had no other neurological disease that could affect the measurement results. All selected patients signed an informed consent to be included in the study. The study was approved by the Ethics Committee.